Agilent to Acquire Biovectra for $925M, Expanding CDMO Portfolio
Agilent has agreed to acquire Biovectra for $925 million, the companies said today, in a deal intended to expand the buyer’s contract development and manufacturing (CDMO) portfolio to the production of fast-growing modalities that include messenger RNA ( …